Boadilla del Monte, Spain Clinical Trials

A listing of Boadilla del Monte, Spain clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 157 clinical trials
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder cancer
bladder carcinoma
urothelial carcinoma
metastatic urothelial carcinoma
Hospital Puerta De Hierro
 (4.7 away) Contact site
  • 22 views
  • 14 Dec, 2020
  • +63 other locations
featured
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced solid tumors where the efficacy of PD-1 inhibitors has previously been established.  

solid tumors
solid tumor
Hospital Puerta De Hierro
 (4.7 away) Contact site
  • 45 views
  • 14 Dec, 2020
  • +52 other locations
featured
Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-7)

This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS.

KRAS
pembrolizumab
Hospital Universitario Fundación Jiménez Díaz
 (8.2 away) Contact site
  • 0 views
  • 10 Jun, 2021
  • +32 other locations
KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684) or MK-5890 in treatment-nave participants with advanced squamous or non-squamous NSCLC. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

lung carcinoma
cancer chemotherapy
paclitaxel
pemetrexed
stage iv non-small cell lung cancer
Hospital Universitario Quiron Madrid ( Site 0091)
 (3.7 away) Contact site
  • 2 views
  • 26 Apr, 2021
  • +24 other locations
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis

This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.

Hospital Universitario de Fuenlabrada
 (8.2 away) Contact site
  • 32 views
  • 01 Jun, 2021
  • +240 other locations
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels. This study is part of HepB Wings Platform Trial (PLATFORMPAHPB2001).

Hosp. Univ. Pta. de Hierro Majadahonda
 (4.7 away) Contact site
  • 6 views
  • 01 Mar, 2020
  • +31 other locations
Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

The purpose of this study is to determine if LCZ696 is safe, tolerable and can improve exercise capacity (via improved peak VO2) in non-obstructive HCM patient population over the course of 50 weeks of treatment.

cpet
hypertrophy
exercise test
cardiopulmonary exercise testing
hypertrophic obstructive cardiomyopathy
Novartis Investigative Site
 (4.7 away) Contact site
  • 2 views
  • 16 May, 2021
  • +15 other locations
A Safety Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale.

Clinica Universidad de Navarra (Madrid)
 (9.7 away) Contact site
  • 101 views
  • 12 Mar, 2021
  • +34 other locations
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack …

angiography
troponin
ck-mb
clot
antiplatelet therapy
Hospital Cl nico Universitario San Carlos
 (8.2 away) Contact site
  • 57 views
  • 09 Jun, 2021
  • +192 other locations
SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Primary Objectives: Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: To assess the …

platinum-based chemotherapy
squamous non-small cell lung cancer
cancer
measurable disease
Investigational Site Number 7240004
 (8.2 away) Contact site
  • 0 views
  • 14 Jun, 2021
  • +12 other locations